Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 44 articles:
HTML format
Text format



Single Articles


    November 2017
  1. OKTAY K, Taylan E, Rodriguez-Wallberg KA, Bedoschi G, et al
    Goserelin Does Not Preserve Ovarian Function Against Chemotherapy-Induced Damage.
    Ann Oncol. 2017 Nov 3. doi: 10.1093.
    PubMed     Text format    


    October 2017
  2. NABIEVA N, Kellner S, Fehm T, Haberle L, et al
    Patient and tumor characteristics and their influence on early therapy persistence with letrozole in postmenopausal patients with early breast cancer.
    Ann Oncol. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  3. LORUSSO D, Pignata S
    Role of adjuvant chemotherapy in early stage endometrioid and clear cell ovarian cancer.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format    


  4. OSELEDCHYK A, Leitao MM Jr, Konner J, O'Cearbhaill RE, et al
    Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013.
    Ann Oncol. 2017 Sep 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  5. REGAN MM, Walley BA, Francis PA, Fleming GF, et al
    Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT.
    Ann Oncol. 2017;28:2225-2232.
    PubMed     Text format     Abstract available


    August 2017
  6. DEL MASTRO L, Lambertini M
    Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: the last piece of the puzzle?
    Ann Oncol. 2017;28:1683-1685.
    PubMed     Text format    


    July 2017
  7. COLOMBO N, Creutzberg C, Querleu D, Barahona M, et al
    Appendix 5: Endometrial cancer: eUpdate published online 8 June 2017 (www.esmo.org/Guidelines/Gynaecological-Cancers).
    Ann Oncol. 2017;28.
    PubMed     Text format    


  8. MARTH C, Landoni F, Mahner S, McCormack M, et al
    Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2017;28.
    PubMed     Text format    


    June 2017
  9. RONCOLATO FT, Gibbs E, Lee CK, Asher R, et al
    Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.
    Ann Oncol. 2017 Jun 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  10. CONDORELLI R, Andre F
    Combining PI3K and PARP inhibitors for breast and ovarian cancer tratement.
    Ann Oncol. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  11. BAMIAS A, Gibbs E, Khoon Lee C, Davies L, et al
    Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
    Ann Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. LEONARD R, Adamson D, Bertelli G, Mansi J, et al
    GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
    Ann Oncol. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017;28:996-1004.
    PubMed     Text format     Abstract available


    April 2017
  14. EYSBOUTS YK, Ottevanger PB, Massuger LFAG, IntHout J, et al
    Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia (GTN) be simplified? A new retrospective analysis from a nationwide data-set.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. CHIANNILKULCHAI N, Pautier P, Genestie C, Bats AS, et al
    Networking for ovarian rare tumors: a significant breakthrough improving disease management.
    Ann Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. RAY-COQUARD I, Lorusso D
    Immunotherapy and Epithelial Ovarian Cancer: a double-edged sword?
    Ann Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format    


    March 2017
  17. POVEDA A, Del Campo JM, Ray-Coquard I, Alexandre J, et al
    Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  18. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. KARAM A, Ledermann JA, Kim JW, Sehouli J, et al
    Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  20. MCGEE J, Bookman M, Harter P, Marth C, et al
    5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors.
    Ann Oncol. 2017 Jan 24. pii: mdx010. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. POWELL MA
    Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard.
    Ann Oncol. 2017;28:9-10.
    PubMed     Text format    


    December 2016
  22. KHOSROW-KHAVAR F, Filion KB, Al-Qurashi S, Torabi N, et al
    Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ann Oncol. 2016 Dec 20. pii: mdw673. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. POWELL MA
    Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: The appropriate standard.
    Ann Oncol. 2016.
    PubMed     Text format    


  24. WILSON MK, Pujade-Lauraine E, Aoki D, Mirza MR, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  25. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. LEARY AF, Quinn M, Fujiwara K, Coleman RL, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): Clinical trial design for rare ovarian tumours.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  27. MESNAGE SJ, Auguste A, Genestie C, Dunant A, et al
    Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  28. LIU JF, Moore KN, Birrer MJ, Berlin S, et al
    Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Ann Oncol. 2016;27:2124-2130.
    PubMed     Text format     Abstract available


  29. WEIDERPASS E, Botteri E
    Ovarian cancer mortality trends: which factors are involved?
    Ann Oncol. 2016;27:1977-1978.
    PubMed     Text format    


  30. MANGILI G, Sigismondi C, Lorusso D, Cormio G, et al
    The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  31. STELLOO E, Jansen AM, Osse EM, Nout RA, et al
    Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  32. MALVEZZI M, Carioli G, Rodriguez T, Negri E, et al
    Global trends and predictions in ovarian cancer mortality.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  33. LEDERMANN JA, Sessa C, Colombo N
    appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies).
    Ann Oncol. 2016;27.
    PubMed     Text format    


  34. PALUCH-SHIMON S, Cardoso F, Sessa C, Balmana J, et al
    Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
    Ann Oncol. 2016;27.
    PubMed     Text format    


    August 2016
  35. BENTIVEGNA E, Gouy S, Maulard A, Pautier P, et al
    FERTILITY-SPARING SURGERY IN EPITHELIAL OVARIAN CANCER: A SYSTEMATIC REVIEW OF ONCOLOGICAL ISSUES.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  36. CHO Y, Kim KH, Yoon HI, Kim GE, et al
    Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  37. PAPATLA K, Huang M, Slomovitz B
    The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  38. LINDEMANN K, Kristensen G, Mirza MR, Davies L, et al
    Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  39. RUSTIN GJ, Hall MR
    Is CA125 useful in monitoring patients with platinum resistant ovarian cancer?
    Ann Oncol. 2016.
    PubMed     Text format    


  40. MCNEISH IA
    Prognostic pathways in early stage ovarian cancer - can gene expression transcend histological subtype?
    Ann Oncol. 2016.
    PubMed     Text format    


  41. VOLGGER BM, Windbichler GH, Zeimet AG, Graf AH, et al
    LONG-TERM SIGNIFICANCE OF URINARY NEOPTERIN IN OVARIAN CANCER - A STUDY BY THE AUSTRIAN ASSOCIATION FOR GYNECOLOGIC ONCOLOGY (AGO).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  42. TRILLSCH F, Mahner S, Hilpert F, Davies L, et al
    Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  43. CALURA E, Paracchini L, Fruscio R, Di Feo A, et al
    A prognostic regulatory pathway in stage I Epithelial Ovarian Cancer: new hints for the poor prognosis assessment.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    December 2014
  44. SCHOFFSKI P, Besse B, Gauler T, de Jonge MJ, et al
    Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell l
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: